Jul 21, 2021

Unilabs and Ibex to deploy AI cancer tool across Europe

2 min
Unilabs and Ibex to deploy AI cancer tool across Europe
Unilabs has signed a deal with Ibex to roll out its AI-driven cancer diagnostics platform across Europe

Diagnostics firm Unilabs has signed a deal with Ibex Medical Analytics that will see Ibex's AI platform for diagnosing cancer rolled out across 16 European countries. 

The multi-tissue AI-powered Galen™ platform helps clinicians diagnose cancer quickly and accurately. Using algorithms developed with advanced machine learning, the Galen platform is trained to analyse images from tissue biopsies, providing insights to pathologists. 

These insights include case prioritisations, cancer heatmaps, tumour grading and measurement, and streamlined reporting tools. 

The Galen platform is CE marked for breast and prostate cancer detection in multiple workflows, and was recently granted Breakthrough Device Designation by the US Food and Drug Administration (FDA). 

"This cutting-edge AI technology will help our teams quickly prioritise urgent cases, speed up diagnosis, and improve quality by adding an extra set of digital eyes” Dr Christian Rebhan, Unilabs’ Chief Medical and Operations Officer explained. 

“When it comes to cancer, the earlier you catch it, the better the prognosis – so getting us critical results faster will help save lives. The partnership with Ibex underlines Unilabs’ pioneering role in digital pathology and represents yet another step in our ambition to become the most digitally enabled provider of diagnostic services in Europe.”

Unilabs is one of Europe’s largest diagnostics companies, and has been heavily invested in the COVID-19 response. Using dedicated new labs in Portugal, the Netherlands, Switzerland, the UK and the UAE, the company has capacity to process more than 500,000 COVID-19 tests per week.

It is the first pan-European diagnostics provider to deploy the Galen platform. The roll out will begin in Sweden, before being implemented across the continent. 

Share article